Business Wire

CO-CSG

Share
CSG Earns Recognition from Leading Analyst Firms

Communication service providers (CSPs) are racing to modernize their operations and deliver dynamic and personalized experiences for their customers. To leverage automation, intelligence and orchestration, they’re working to improve the customer experience across all touchpoints. In 2023, CSG® (NASDAQ: CSGS)’s award-winning solutions and integrated omnichannel approach helped global brands transform their customer experience, earning CSG recognition from leading analyst firms Gartner, Frost & Sullivan, Kaleido Intelligence, MGI and Quadrant Knowledge Solutions.

In recent months, CSG has been recognized as:

  • A Niche player in the 2023 Gartner® Magic Quadrant™ for Configure, Price and Quote Application Suites
    • CSG Quote & Order enables CSPs to configure products with live pricing, creating comprehensive orders that seamlessly flow from quotes to fulfillment. An API-powered CPQ solution built for complex B2B services, it provides CSPs with the composability and order management capabilities they need to drive faster time to revenue and deliver a better overall customer experience.
  • A Leader in the 2023 Frost Radar for 5G Revenue Management and Monetization
    • CSG enables CSPs to reduce reliance on multi-vendor solutions, lowering time to market and total cost of ownership by integrating charging, billing, policy control and interconnect. The depth of its capability portfolio, modular SaaS platforms and unique partnership-driven approach earn CSG a leadership placement for its ability to monetize a variety of 5G use cases on a single SaaS platform.
    • Frost & Sullivan writes: "CSG has proven how it can integrate assets from a network and a messaging portfolio to provide a one-stop shop for CSPs. The company has mastered the challenges of hybrid operations."
  • A Leader in the 2023 MGI 360 Rating: The Agile Billing Top 50 Buyers Guide
    • MGI recognized CSG Ascendon as “a good fit for organizations looking to create modern monetization capability to support new business initiatives”. The report states: "CSG Ascendon represents a multi-tenant SaaS approach to monetization tools for B2C-oriented digital services. It has a sophisticated product catalog capability, can support customer and product hierarchies and abstract complex pricing methods, including usage."
  • A Champion in the 2023 Kaleido Intelligence Roaming Vendor Hub – Clearing & Settlement
    • CSG Retail Roaming Management platform enables CSPs to build new dynamic digital wholesale services and to drive the associated business models over 4G and 5G networks of any size. Kaleido notes: The CSG platform is "agile and extensible, bringing significant new functionality with minimal disruption to existing infrastructure."
    • CSG was also recognized as a High-Flyer in the Roaming Analytics & VAS and Fraud Management rating categories.
  • A Leader in the 2023 SPARK Matrix: Configure, Price & Quote
    • CSG Quote & Order helps service providers deliver complex digital offerings by addressing the dual challenges of B2B2X relationships with customers and partners. Its comprehensive capabilities, impressive customer references, well-defined roadmap and vision and a highly scalable product suit earn CSG strong ratings for technological excellence and customer impact.
    • Quadrant Knowledge Solutions notes: "CSG offers a leading CPQ portfolio, customized specifically for the telecom industry, apart from also having strong third-party partnerships, robust functional capabilities and an extensive customer base."

Beyond these recognitions, CSG is mentioned in the 2023 Gartner Market Guide for CSP Customer Management and Experience Solutions, which CIOs can use to shape their sourcing strategy by understanding the investments and directions of representative vendors. CSG was also mentioned in the 2022 Gartner Market Guide for Revenue Management and Monetization as one of 20 vendors providing a wide variety of solutions, offering different portfolios, deployment/implementation approaches and focus areas for various segments of CSPs.

“Global operators trust CSG to modernize their business because we've demonstrated time and again that we understand their customers’ needs and provide the capabilities they need to drive tangible growth,” said Chad Dunavant, Chief Product & Strategy Officer, CSG. “The breadth and depth of our portfolio support CSPs regardless of their focus on B2C, B2B or B2B2X as we empower them to deliver new services faster than competitors, increase customer satisfaction and boost brand loyalty. This has been our bread and butter for 40+ years and is why industry analysts consistently rank CSG among the leading BSS solution providers across the industry.”

For more information about CSG, visit www.csgi.com.

Gartner, Magic Quadrant for Configure, Price and Quote Application Suites, Mark Lewis, Dayna Radbill, 11 December 2023.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About CSG

CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.

Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123732657/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye